Quoin Pharmaceuticals, Ltd.
QNRXHealthcare|Biotechnology|US
$3.65
-0.20 (-5.19%)
DCF Value
$2547.50
Tangible Book / Share
$5.63
Cash / Share
$2.00
Financials
Financial Snapshot
Market Cap
$7.3M
Enterprise Value
-$2.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$19.7M
Cash & Investments
$10.1M
Net Cash
$10.1M
Free Cash Flow (TTM)
$42.90B
Operating CF (TTM)
$42.90B
Debt/Equity
0.00
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $8.0M | $8.0M | $4.8M | $5.2M | $323.8K | $7.5M | $12.9M | $10.7M | $14.1M | $3.82B | $10.1M | |
| Operating Cash Flow | -$3.8M | -$5.0M | -$6.6M | -$5.7M | -$1.3M | -$5.7M | -$8.5M | -$7.9M | -$7.9M | -$13.5M | $42.90B | |
| Free Cash Flow | -$4.1M | -$5.1M | -$6.8M | -$5.7M | -$1.5M | -$6.3M | -$8.7M | -$7.9M | -$7.9M | -$13.5M | $42.90B | |
| Capital Expenditure | -$330.6K | -$74.5K | -$182.5K | -$34.5K | -$125.0K | -$625.0K | -$250.0K | $3.77 | $0.00 | $4.00 | $1.00 | |
| Financing Cash Flow | $9.1M | $4.4M | $3.5M | $6.1M | $1.8M | $13.5M | $14.0M | $5.2M | $11.0M | $18.0M | -$57.08B |
R&D Spending
R&D (TTM)
$12.9M
R&D Intensity
—
R&D Growth vs Prior
+31.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$280.0K | $0.00 | -$280.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $8.3M | $5.9M | $8.3M | $45.6K | $244.2K | $1.6M | $2.7M | $3.3M | $3.6M | $9.8M | $12.9M | |
| R&D % of Revenue | -2948.6% | — | -2948.6% | — | — | — | — | — | — | — | — | |
| SG&A | $8.0M | $4.2M | $8.0M | $1.5M | $1.4M | $4.5M | $6.6M | $6.1M | $5.9M | $6.5M | $7.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$280.0K | $0.00 | -$280.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $89.1K | $104.2K | $125.7K | $227.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $25.4K | |
| Gross Profit | -$369.1K | -$104.2K | -$405.7K | -$227.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$25.4K | |
| R&D | $8.3M | $5.9M | $8.3M | $45.6K | $244.2K | $1.6M | $2.7M | $3.3M | $3.6M | $9.8M | $12.9M | |
| SG&A | $8.0M | $4.2M | $8.0M | $1.5M | $1.4M | $4.5M | $6.6M | $6.1M | $5.9M | $6.5M | $7.3M | |
| Operating Income | $15.3M | $10.2M | $15.3M | -$1.6M | -$1.7M | -$6.1M | -$9.3M | -$9.4M | -$9.5M | -$16.3M | -$15.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $412.3K | $1.2M | $1.1M | $714.1K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $15.3M | $10.2M | $15.3M | -$1.6M | -$2.1M | -$21.5M | -$9.4M | -$8.7M | -$9.0M | -$15.8M | -$19.7M | |
| Net Income | $15.3M | $10.2M | $15.3M | -$1.6M | -$2.1M | -$21.5M | -$9.4M | -$8.7M | -$9.0M | -$15.8M | -$19.7M | |
| EPS (Diluted) | -160847.00 | -257489.00 | -158862.00 | -16307.00 | -1290.96 | -2490.26 | -11.42 | -11781.00 | -2352.81 | -10.63 | -9.15 | |
| EBITDA | -$3.9M | -$7.8M | -$5.5M | -$1.5M | -$1.6M | -$20.3M | -$8.6M | -$8.6M | -$8.9M | -$15.7M | -$15.0M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.82 | 0.00 | 0.00 | 1.50 | 5.04 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $4.0M | $4.8M | $5.2M | $323.8K | $7.5M | $2.9M | $2.4M | $3.6M | $3.82B | $10.1M | |
| Short-Term Investments | $6.4M | $4.0M | $0.00 | $0.00 | $0.00 | $0.00 | $10.0M | $8.3M | $10.4M | $14.9M | $0.00 | |
| Total Current Assets | $8.4M | $8.2M | $5.0M | $5.4M | $465.2K | $8.2M | $13.4M | $11.3M | $14.9M | $20.0M | $34.4M | |
| Total Assets | $8.8M | $8.7M | $5.5M | $6.2M | $1.4M | $9.4M | $14.5M | $12.2M | $15.7M | $20.4M | $34.7M | |
| Total Current Liabilities | $905.5K | $1.2M | $1.3M | $1.1M | $8.0M | $4.6M | $3.5M | $3.6M | $4.2M | $5.5M | $4.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.4M | $3.3M | $1.8M | $1.9M | $8.0M | $8.7M | $7.1M | $6.5M | $6.5M | $7.3M | $6.0M | |
| Stockholders' Equity | $7.4M | $5.4M | $3.7M | $4.3M | -$6.6M | $657.0K | $7.4M | $5.7M | $9.2M | $13.1M | $28.7M | |
| Retained Earnings | -$9.3M | -$18.4M | -$22.5M | -$29.2M | -$6.6M | -$28.1M | -$37.5M | -$46.2M | -$55.2M | -$71.0M | -$86.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M | -$5.0M | -$6.6M | -$5.7M | -$1.3M | -$5.7M | -$8.5M | -$7.9M | -$7.9M | -$13.5M | $42.90B | |
| Capital Expenditure | -$330.6K | -$74.5K | -$182.5K | -$34.5K | -$125.0K | -$625.0K | -$250.0K | $3.77 | $0.00 | $4.00 | $1.00 | |
| Free Cash Flow | -$4.1M | -$5.1M | -$6.8M | -$5.7M | -$1.5M | -$6.3M | -$8.7M | -$7.9M | -$7.9M | -$13.5M | $42.90B | |
| Investing Cash Flow | -$4.7M | $2.8M | $3.8M | -$30.3K | -$125.0K | -$625.0K | -$10.1M | $2.2M | -$1.9M | -$4.3M | $4.26B | |
| Financing Cash Flow | $9.1M | $4.4M | $3.5M | $6.1M | $1.8M | $13.5M | $14.0M | $5.2M | $11.0M | $18.0M | -$57.08B | |
| Issuance of Stock | $9.1M | $4.4M | $3.5M | $6.3M | -$142.3K | $0.00 | $14.8M | $5.8M | $11.6M | $18.8M | $18.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$146.5K | $910.0K | $3.5M | -$311.7K | -$600.0K | -$600.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $764.0K | $1.1M | $1.3M | $1.1M | -$2.49B | |
| Net Change in Cash | $653.5K | $2.3M | $809.8K | $476.1K | -$4.9M | $7.2M | -$4.6M | -$459.4K | $1.2M | $194.8K | $2.3M |
Dilution Tracker
Shares outstanding grew 91596.7% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+91596.7%
Stock Issuance (TTM)
$18.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.82 | 0.00 | 0.00 | 1.50 | 5.04 | |
| Change vs Prior % | — | 20.0% | 16.7% | 725.7% | 465.4% | 427.8% | 9451.3% | -99.9% | 420.7% | 39051.4% | 236.5% | |
| Stock Issuance | $9.1M | $4.4M | $3.5M | $6.3M | -$142.3K | $0.00 | $14.8M | $5.8M | $11.6M | $18.8M | $18.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $764.0K | $1.1M | $1.3M | $1.1M | -$2.49B |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 131.8% | — | 144.9% | — | — | — | — | — | — | — | — | |
| Operating Margin % | -5470.4% | — | -5470.4% | — | — | — | — | — | — | — | — | |
| Net Margin % | -5470.4% | — | -5470.4% | — | — | — | — | — | — | — | — | |
| EBITDA Margin % | 1394.9% | — | 1953.1% | — | — | — | — | — | — | — | — | |
| FCF Margin % | 1463.4% | — | 2413.0% | — | — | — | — | — | — | — | — | |
| ROE % | 206.9% | 187.3% | 411.1% | -36.3% | 31.7% | -3266.6% | -126.7% | -153.4% | -97.4% | -120.5% | -144.4% | |
| ROA % | 173.8% | 116.3% | 277.3% | -25.3% | -152.1% | -229.4% | -64.9% | -71.4% | -57.1% | -77.5% | -56.6% | |
| ROIC % | 191.5% | 134.4% | 363.7% | -29.8% | 31.0% | -126.8% | -84.7% | -109.2% | -82.7% | -109.7% | -50.8% | |
| R&D / Revenue % | -2948.6% | — | -2948.6% | — | — | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 100.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -1920.3% | 71.8% | -289.3% | 44.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 689.5% | -33.6% | 50.6% | -110.2% | -7.0% | -263.0% | -52.7% | -1.3% | -1.6% | -71.0% | |
| Net Income | 685.1% | -33.6% | 50.6% | -110.2% | -34.3% | -924.3% | 56.3% | 7.4% | -3.2% | -76.3% | |
| EPS (Diluted) | -13076891.9% | -60.1% | 38.3% | 89.7% | 92.1% | -92.9% | 99.5% | -103061.1% | 80.0% | 99.5% | |
| Operating Cash Flow | -89.9% | -32.2% | -32.0% | 13.2% | 76.5% | -327.3% | -48.3% | 7.3% | 0.1% | -72.3% | |
| Free Cash Flow | -98.0% | -23.3% | -33.7% | 15.0% | 74.5% | -333.5% | -37.6% | 9.9% | 0.1% | -72.3% | |
| R&D Expense | 444.4% | -28.6% | 40.1% | -99.4% | 434.8% | 540.1% | 71.0% | 23.8% | 8.9% | 172.1% | |
| SG&A Expense | 649.1% | -47.2% | 89.5% | -81.0% | -5.9% | 215.6% | 46.3% | -7.8% | -2.4% | 9.5% | |
| Total Assets | 156.6% | -0.7% | -36.9% | 11.8% | -77.7% | 579.1% | 54.5% | -15.8% | 29.1% | 29.8% | |
| Book Value / Share | 23343899.0% | -38.9% | -41.2% | -86.0% | -127.2% | 101.9% | -88.2% | 85599.9% | -68.8% | -99.6% | |
| Debt | 0.0% | -100.0% | 0.0% | 0.0% | 290.6% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | -100.0% | 20.0% | 16.7% | 725.7% | 465.4% | 427.8% | 9451.3% | -99.9% | 420.7% | 39051.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.64
10Y Low / Med / High0.01 / 2.07 / 125.42
EV/EBITDA0.19
10Y Low / Med / High0.27 / 0.40 / 241.74
EV/Revenue0.00
P/FCF0.00
Intrinsic Value Models (per share)
DCF Value
$2547.50
Tangible Book / Share
$5.63
Net Current Assets / Share
$14.12
Graham Net-Net
$0.80
Cash / Share
$2.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -2.02 | -2.85 | -1.39 | -2.86 | -35.14 | -3.84 | -52.22 | -0.01 | -0.01 | -1.36 | -0.40 | |
| P/S Ratio | -28.97 | 0.00 | -27.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1.10 | 4.06 | 2.07 | 3.14 | -11.22 | 125.42 | 66.33 | 0.02 | 0.01 | 1.65 | 0.64 | |
| EV/EBITDA | -1.66 | -2.32 | -0.54 | -5.55 | -47.90 | -3.70 | -57.03 | 0.27 | 0.40 | 241.74 | 0.19 | |
| EV/Revenue | -23.20 | 0.00 | -10.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-3.15
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $13.1M | $12.1M | $16.3M |
| Net Income | -$9.1M | -$4.1M | -$2.5M |
| EPS | $-6.08 | $-2.71 | $-1.65 |
| # Analysts (EPS) | 2 | 3 | 3 |